Efficacy of statin monotherapy or in combination with coenzyme a capsule in patients with metabolic syndrome and mixed dyslipidemia.

Autor:	Lai J; Department of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China., Wu B; Department of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China., Xuan T; Department of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China., Xia S; Department of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China., Liu Z; Department of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China., Chen J; Department of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Jazyk:	angličtina
Zdroj:	Journal of clinical medicine research [J Clin Med Res] 2015 Jun; Vol. 7 (6), pp. 446-52. Date of Electronic Publication: 2015 Apr 08.
DOI:	10.14740/jocmr2124w
Abstrakt:	Background: Patients with metabolic syndrome are at increased risk for cardiovascular disease. Combination lipid-lowering therapy is often needed in patients with metabolic syndrome and mixed dyslipidemia. The aim of this study was to compare the effect of statin combined with a new hypolipidemic agent, coenzyme A (CoA) with moderate-dose statin monotherapy in subjects with metabolic syndrome and mixed dyslipidemia by evaluating data from a subgroup of patients with metabolic syndrome and mixed dyslipidemia from a previously conducted randomized study. Methods: In the present post hoc analysis, 212 patients were included, receiving statin monotherapy (n = 94) or statin combined with CoA 400 U/day (n = 118) for 8 weeks. The lipoprotein profile was determined at baseline and week 8 visits. Attainment of low-density lipoprotein-cholesterol (LDL-C) < 100 mg/dL, non-high-density lipoprotein-cholesterol (HDL-C) < 130 mg/dL, and the combined goal of these two parameters was also evaluated. Results: The mean percent change was more prominent with CoA plus statin compared with placebo plus statin in triglyceride (TG) (-32.5% vs. -8.7%, respectively; P = 0.0002), total cholesterol (-9.6% vs. -3.6%, P = 0.013), LDL-C (-7.5% vs. 2.1%, P = 0.033), and non-HDL-C (-14.3% vs. -6.4%, P = 0.011). Treatment with CoA plus statin resulted in larger percentages of participants attaining lipid goals for LDL-C (70.3% vs. 56.4%, P = 0.044), non-HDL-C (60.2% vs. 45.7%, P = 0.039), and the combined goal of LDL-C and non-HDL-C (57.6% vs. 42.6%, P = 0.038) than statin monotherapy. Conclusion: These results demonstrate that CoA plus statin therapy was more effective in improving lipoprotein parameters than statin alone in patients with metabolic syndrome and mixed hyperlipidemia.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu